Announcements – Neville Registrars

24 NOVEMBER 2017

APC Tech Group PLC : New Time Synchronisation Partnership

RNS Number : 3869X APC Technology Group PLC 24 November 2017 24th November 2017 APC Technology Group PLC ("APC" or the "Group") APC Technology Group expands time synchronisation product range following new partnership signing APC Technology Group PLC (AIM: APC), the design, specification and distributor of……

23 NOVEMBER 2017

Osirium Technologies : Contract win

RNS Number : 2857X Osirium Technologies PLC 23 November 2017 For immediate release 23 November 2017 Osirium Technologies plc ("Osirium" or "Group") Contract win with a leading law firm Osirium Technologies plc (AIM: OSI.L), a UK headquartered cyber-security SaaS provider, is pleased to……

21 NOVEMBER 2017

EU Supply PLC : Contract Win

RNS Number : 0207X EU Supply PLC 21 November 2017 21 November 2017 EU Supply plc ("EU Supply", the "Company" or the "Group") Contract win EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that it has received its fourth contract (the "Contract")……

RNS Number : 0207X

EU Supply PLC

21 November 2017

EU Supply plc

("EU Supply", the "Company" or the "Group")

Contract win

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that it has received its fourth contract (the "Contract") pursuant to the framework agreement entered into with an existing customer (the "Customer") for additional services to its CTMTM platform which was announced by the Company on 16 June 2017 (the "Agreement").

The Agreement is for 3 years with a further year at the Customer's option and has a total value of up to €3.6m. The Contract comprises customer-paid enhancements and is expected to generate revenues of approximately €675k, bringing the total value of the contracts called-off under the Agreement to date to, in aggregate, approximately €1.9m.

In order to free up capacity to deliver the anticipated increased growth in enhancements and integrations for existing and new customers expected in 2018, the Company will accelerate the delivery of half of the Contract in the remainder of this year. As a result, the Board expects that the Group's revenues for the year ending 31 December 2017 will slightly exceed market expectations while, due to the increased cost of delivering the Contract by using consultants, the Group's operating profit for the year ending 31 December 2017 is expected to be in line with market expectations.

FURTHER ENQUIRIES

EU Supply PLC	Tel: 020 7127 4545
Thomas Beergrehn, CEO
Fredrik Wallmark, CFO

Stockdale Securities	Tel: 020 7601 6100
Tom Griffiths, Ed Thomas

A copy of this announcement is available at www.eu-supply.com.

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for esourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 8,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTQBLFLDFFXFBQ

Close

21 NOVEMBER 2017

Genedrive PLC : genedrive plc awarded Innovate UK grant

RNS Number : 0378X Genedrive PLC 21 November 2017 For release: 21 November 2017 genedrive plc ("genedrive" or the "Company") genedrive plc awarded £600,000 Innovate UK grant Award to support the development of a centrifuge-free plasma separation consumable for its Genedrive® HCV assay genedrive……

20 NOVEMBER 2017

Verditek PLC : Renewal and Extension of Contract with Media One

RNS Number : 9054W Verditek PLC 20 November 2017 20 November 2017 Verditek PLC ("Verditek" or the "Company") Renewal and Extension of Contract with Media One Following Successful Completion of Trial Verditek plc, (AIM: VDTK), the clean technology company, announces that its 51% owned subsidiary, Greenflex……

RNS Number : 9054W

Verditek PLC

20 November 2017

Verditek PLC

("Verditek" or the "Company")

Renewal and Extension of Contract with Media One Following Successful Completion of Trial

Verditek plc, (AIM: VDTK), the clean technology company, announces that its 51% owned subsidiary, Greenflex Energy Limited ("Greenflex"), an Italian based manufacturing solar photovoltaic ("PV") technology company, has renewed and extended its contract with Media One s.r.l. ("Media One"), one of Italy's largest out of home advertising agencies, following the successful completion of the initial trial contract.

The initial trial contract, which was won in a competitive tender process, saw Greenflex supply and install its solar PV technology at a bus shelter in the province of Rimini, Italy, in September 2017. Following successful completion of the trial, the Company has signed a contract with Media One to extend the supply and installation of its solar PV material to approximately 20 further bus shelters along the Rimini-Riccione bus line in Italy as this new line is completed.

Additionally, Media One has asked Greenflex for a proposal to develop a solution for standalone out of home advertising such as billboards which are currently not lit, enhancing the attractiveness of this communication channel for potential advertisers. The market opportunity within Italy's out of home advertising is significant, with Media One alone operating thousands of advertising billboards across the country.

Verditek's solar PV technology has significant product innovations compared to competing technologies including interconnectivity of individual PV cells, lightness and its unique flexible design integrates the material into the design of the out of home advertising units offering a greater level of security and architectural integrity.

Verditek's CEO, Theo Chapman, said: "We are delighted to have successfully completed this initial trial contract order with Media One, which we believe has demonstrated our solar PV technology as a best in class solution for solar power generation for multiple industries.

"One of the main cost constraints in the rapid roll out of digital advertising boards across Italy is the high cost of connection to grid power. We have now shown that there is an effective low-cost alternative that is clean and green and, most importantly, allows the media owners to install and upgrade their units to 24/7 advertising opportunities without having to wait to be hooked up to the grid."

Media One Sales Director, Mr Marco Stefanelli, stated: "Our objective is to always provide the best platform for our clients – who are some of Italy's leading advertisers – to communicate with their customers. It is so important that their brands and messages appear in first class environments that are sustainable. Greenflex products allow our clients to showcase their brands using the power of the sun. That is a message that resonates with all of them.

"We are very pleased with Greenflex's ability to work with us to create a solution that complements our existing investments in media hardware and software and allows us to turn more of our advertising sites into 24/7 advertising solutions".

Enquiries:

Verditek plc

Geoffrey Nesbitt (Non-Executive Chairman)

Theodore Chapman (Chief Executive Officer)

+44 (0) 20 7129 1110

[email protected]

Stockdale Securities Limited (NOMAD and Broker)

Antonio Bossi

Hanan Lee

+44 (0) 20 7601 6100

Yellow Jersey PR (PR & IR)

Georgia Colkin

Harriet Jackson

Henry Wilkinson

+44 (0) 7825 916 715

+44 (0) 7544 275 882

+44 (0) 7951 402 336

Notes to Editors

Verditek plc

AIM listed Verditek plc is a holding company with three businesses operating within the clean technology sector. The Company has a unique liquid gas absorption technology expected to revolutionise the global CO2 capture industry; two solar manufacturing production lines in San Marino each of 25MWp (total 50MWp) producing what is believed to be an innovative and un-paralleled solar PV building material; and a pioneering filtration deodorisation technology, which is commercially proven and tackles a wide range of odours within air and water at a high efficiency.

For more information please visit or contact the following: https://www.verditek.plc.uk/

Media One s.r.l

Media One s.r.l is a leading Italian out of home advertising agency. The agency specialises in large format outdoor advertising and has numerous partnerships, including with Ferrovie dello Stato Italiane (the government-owned holding company that manages infrastructure and services on the Italian rail network), for whom it exclusively manages all advertising across thousands of stations in the country. Media One also currently manages advertising for the transport network in the Italian province of Rimini. The agency continues to grow and is expanding into other business channels including sponsorship opportunities on the facades of private and public buildings in Italy.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTBLBLTMBABBPR

Close

16 NOVEMBER 2017

EU Supply PLC : Contract Win

RNS Number : 6343W EU Supply PLC 16 November 2017 16 November 2017 EU Supply plc ("EU Supply", the "Company" or the "Group") Contract win EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that the Norwegian Road Authority ("Nye Veier") has declared……

14 NOVEMBER 2017

Clean Invest Africa Plc : First Day of Dealings on NEX

14 November 2017 CLEAN INVEST AFRICA PLC (???CIA??? or the ???Company???) Admission to the NEX Exchange Growth Market Clean Invest Africa Plc, an Investment Vehicle for the purpose of identifying investment opportunities and acquisitions in renewable and clean energy projects/companies or alternative technologies that are used in a socially and……

14 November 2017

CLEAN INVEST AFRICA PLC

(???CIA??? or the ???Company???)

Admission to the NEX Exchange Growth Market

Clean Invest Africa Plc, an Investment Vehicle for the purpose of identifying investment opportunities and acquisitions in renewable and clean energy projects/companies or alternative technologies that are used in a socially and environmentally responsible way that will aid the development of the African continent, with the intention of building a diversified portfolio of assets, is pleased to announce that trading in its Ordinary Shares will commence at 8:00 a.m. today on the NEX Exchange Growth Market (???Admission???), under the ticker CIA and ISIN number GB00BF52QX07.

On Admission, the Company will have net funds of ??512,440 and there will be 156,100,000 Ordinary Shares in issue, which rank pari passu in all respects.

Overview

The Company???s primary strategy is to acquire interests in and to own, assist and manage clean energy companies and projects, including renewable energy projects and projects that create environmental benefits through greenhouse gas emission reductions. Renewable energy can generally be defined as energy (such as electricity, transportation fuels, sources of process heat, etc.) derived from resources that are regenerative or for practical purposes cannot be depleted. Renewable energy technologies may be broadly divided into two categories: (1) production of electricity, from sources such as wind, solar, geothermal, hydro, biomass, or municipal wastes; and (2) production of transportation fuels, such as ethanol and biodiesel. Renewable energy is generally considered to involve relatively less environmental impact than traditional sources of energy. The combustion of renewable fuels typically results in a reduction of greenhouse gases (CO2, methane, nitrous oxide, hydrofluorocarbons, perfluorocarbons and sulphur hexafluoride) produced per unit of energy when compared with traditional sources of energy.

Website: www.cleaninvestafrica.com
Market capitalisation at 1p is ??1,561,000

Samuel Preece, Executive Director of CIA, said: ???The renewable and clean energy requirements in African countries present CIA with an economic opportunity. Increases in the price of fossil fuels have led to a significant improvement in the cost competitiveness of renewable energy versus traditional, non-renewable, sources. We are actively seeking investment opportunities and are pleased to be investing in a space where renewable energy resources may greatly reduce emissions of greenhouse gases.???

Details of Directors

The full names of the Directors of the Company and positions are as follows:

Samuel Toby Preece, Executive Director (aged 41)

Samuel has over 20 years of environmental consulting experience, having completed over 1,500 projects in Europe, Asia, Australia, Middle East, Canada, USA and South America as well as across Africa.

Samuel has overseen the technical evaluation and permitting of alternative energy projects across the UK, Ireland, Europe and Africa. These projects include a wide range of energy technologies including on and offshore wind, solar, tidal, hydroelectric, geothermal, ground source heat pumps, pumped storage, waste to energy, anaerobic biodigestion, and gas to power, in a number of applications.

Samuel spent five years as an in-house technical specialist at an international construction contractor, Laing O???Rourke, working on projects in the technology and energy sectors.

Samuel was previously a director responsible for the UK and Ireland???s environment business line of AECOM, a business that had revenues of approximately US$17.4 billion in the fiscal year to 2016. In this role at AECOM, Sam advised national and multinational clients on the technical feasibility and licencing and permitting of their energy, technology and land asset projects. These projects include energy projects across Africa.

Samuel has access to a network of environmental and energy technical experts located across Africa with local knowledge and technical expertise and currently supports investors and companies looking to grow and seek investment in business and projects in Africa. These currently include renewable energy, green technology projects in southern and sub-Saharan Africa. Sam also advises on Environmental, Social and Governance risks and opportunities for investors, companies and financial institutions including in the energy sector.

Andrew Paul Matharu, Independent Non–Executive Director (aged 48)

Andrew has over 22 years' experience in the oil & gas sector and commenced his career as a Petroleum Engineer with Chevron and Kerr-McGee Oil. Andrew has extensive experience of advising small and mid-cap oil & gas companies in equity capital markets following a variety of corporate finance and institutional equity roles at Cazenove, Bridgewell Securities and Westhouse Securities. His most recent role was in Corporate Development with the Africa-focussed AIM-listed explorer, Tower Resources plc, where he was involved in a number of corporate and asset M&A transactions and capital raisings.

Andrew holds a BEng degree in Chemical Engineering from University of Sheffield, a PhD in Chemical Engineering from the University of Cambridge and is a Chartered Engineer.

Noel Lyons, Non-Executive Director (aged 52)

Noel started his career in the accounting profession and progressed from there to management and director level within various organisations. He has worked for such companies as Amoco/BP, Coca Cola, Kentz Corporation Plc and Oilinvest International, and has worked in diverse locations such as Africa and The Middle East.

Noel has been involved in several listings on AIM and the NEX Exchange Growth Market in both a management and advisory capacity, including as co-founder and, initially, as a non-executive director of Karoo Energy plc. Noel has an MBA and masters in Accounting and Finance.

Directors??? Interests

On Admission the interests of the Directors and their immediate families and, so far as they are aware having made due and careful enquiries, of persons connected with them (all of which are beneficial, unless otherwise stated) (so far as is known to the Directors, or could with reasonable diligence be ascertained by them) (within the meaning of sections 252 to 254 of the UK Companies Act 2006) in the Issued Share Capital are as follows:

*Director*	*Number of Ordinary Shares on Admission*	*% of Issued Share Capital*
Samuel Preece	1,200,000	0.77
Andrew Matharu	1,200,000	0.77
Noel Lyons	9,800,000	6.28

Significant Shareholders

In addition to the Directors holdings disclosed above, the Company has been notified or is aware of the following holdings which will, following Admission, represent more than 3 per cent. of the Issued Share Capital or voting rights of the Company:

*Name*	*Number of Ordinary Shares on Admission*	*% of Issued Share Capital*
Ren?? Carayol	9,800,000	6.28
Jim Nominees	132,500,000	84.88

The Directors of the Company are responsible for the content of this announcement.

For further information, please contact:

The Company
Sam Preece	+ 44 (0) 20 3130 0674
NEX Exchange Corporate Adviser Peterhouse Corporate Finance Limited
Guy Miller/Mark Anwyl	+44 (0) 20 7469 0936

Close

14 NOVEMBER 2017

Neville Registrars welcomes Clean Invest Africa Plc

Neville Registrars is delighted to welcome Clean Invest Africa Plc as the newest addition to its list of client companies. Clean Invest Africa is an Investment Vehicle that will focus on acquiring stakes in clean energy companies, remediation / restoration technologies, waste to energy technologies and other clean energy related projects throughout Africa. ……

13 NOVEMBER 2017

Concepta PLC : Sales Order

RNS Number : 2484W Concepta PLC 13 November 2017 13 November 2017 Concepta plc ("Concepta" or the "Company") £600,000 sales order confirmed Concepta plc (AIM: CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market……

08 NOVEMBER 2017

N4 Pharma PLC : Results of latest nuvec pre-clinical study

RNS Number : 8341V N4 Pharma PLC 08 November 2017 08 November 2017 N4 Pharma Plc ("N4 Pharma" or the "Company") Results of latest nuvec® pre-clinical study N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces the results……

RNS Number : 8341V

N4 Pharma PLC

08 November 2017

N4 Pharma Plc

("N4 Pharma" or the "Company")

Results of latest nuvec® pre-clinical study

N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces the results of the latest study it has conducted for its nuvec® silica nanoparticles ("SiNPs") delivery system.

As well as investigating tolerability, the objective of this study (funded via a biomedical Catalyst Grant) was to determine the in-vivo capacity for the Company's SiNPs to deliver DNA to generate local expression of a protein. This is a key indicator as to whether a vaccine delivery system is likely to successfully generate an immune response. The Company completed two tests in this study, the first was an injection directly into a cancerous tumour and the second was a subcutaneous injection; two routes of administration typically used for vaccination.

In conclusion, a single injection of the SiNPs is effective in delivering DNA to generate localised protein expression at the site of the injection and draining lymph nodes and release cytokines into the systemic circulation. These are all crucial elements for successful cancer therapy treatment. No tolerability issues were encountered for the duration of the study.

Following these results, further in-vivo studies will be conducted to demonstrate the capability of the Company's SiNPs to deliver specific antigens to promote an adaptive immune response (i.e. as a vaccine) or to deliver functional proteins that can have a biological effect and to undertake comparison studies showing how the Company's SiNPs compare to lipid nanoparticles, which are widely used as delivery systems for cancer vaccines and therapies.

Nigel Theobald, CEO of N4 Pharma, commented:

"As well as preparing to take our sildenafil reformulation into clinic, we have been scoping out the potential for our nuvec® delivery system and continue to make encouraging progress demonstrating its capability. This signifies another prominent step forward on the road to commercialising nuvec® .

We now have evidence that our SiNPs have many desirable features for use in either a vaccine approach or to deliver therapeutic proteins to tissues and are uncovering key commercial advantages compared to lipid nanoparticles. This increases the scope of nuvec's® application which in turn enhances the value of the technology to potential commercial partners.

The value of the global nanotechnology drug delivery market is forecast to grow from $4.1 billion in 2014 to $11.9 billion in 2023*.

As nuvec® continues to meet its technical targets, it becomes very clear that we have the potential to become a significant player in this growing market. We will continue its development to determine how best to compete and to take the technology forward."

* source: Transparency Market Research July 2014

Enquiries:

N4 Pharma Plc

Nigel Theobald, CEO,

Via Alma PR

Stockdale Securities

Tom Griffiths

Tel: +44(0)207 601 6100

Beaufort Securities

Elliot Hance

Tel: +44(0)207 382 8300

Alma PR

Josh Royston

Robyn Fisher

Tel: +44(0)778 090 1979

Tel: +44(0)754 070 6191

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

Glossary

Silica nanoparticles (SiNPs)	Small manufactured structures, measured in a narrow size range of nanometres, that are derived from silicon.
Cytokines	Cytokines are cell signalling molecules that aid cell to cell communication in immune responses and stimulate the movement of cells towards sites of inflammation, infection and trauma.
Antigen	An antigen is any substance that causes your immune system to produce antibodies against it. This means your immune system does not recognize the substance, and is trying to fight it off.
Lipid nanoparticles	Lipid nanoparticles are small particles, measured in nanometres, formed through either the complexation or encapsulation of nucleic acids with cationic lipids.
Subcutaneous injection	A subcutaneous injection is a method of administering medication. Subcutaneous means under the skin. In this type of injection, a short needle is used to inject a drug into the tissue layer between the skin and the muscle. Medication given this way is usually absorbed more slowly than if injected into a vein, sometimes over a period of 24 hours.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RESQDLFBDFFFFBB

Close

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Neil Shah / Ben Maddison
Yellow Jersey PR (Financial PR) Sarah Hollins	Tel: +44 (0) 7764 947137